看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
! j6 ^$ I) c0 o2 P( H0 }7 F& \
: D: }$ U0 k, l# c) z; l P* N5 b. `9 i' \1 v& w/ g! C4 ^+ W4 G
Currently available feasibility data for possible combination strategies.
, w" W1 k. k% Q! I) V% M5 ~! H# K————————————————————————————————
# b2 R/ J B; W; BCombination Feasibility according to preliminary data 6 ^1 X) t8 ^* q7 h: V
——————————————————————————————————
1 Y9 ]5 E7 T6 c7 m: vBevacizumab + sorafenib Yes, reduced dose
8 T; s# h* Z. g; l" M; q3 C8 oBevacizumab + sunitinib† No
3 k7 ~# L5 _0 E8 H: I! v7 I( B+ NBevacizumab + temsirolimus Yes ( X7 r* @ B6 X; T; |
Bevacizumab + everolimus Yes
9 z s+ h% }$ }* {& ]/ Z! v pSorafenib + sunitinib ? % a, R; d# q8 T/ Y
Sorafenib + temsirolimus Yes, reduced dose 8 W; X( I g' }* l. W
Sorafenib + everolimus Yes, reduced dose
# ~& g2 x! p- T' j$ K& uSunitinib + temsirolimus† No
) P F+ P& i7 ^Sunitinib + everolimus ?
# T2 U( p7 o3 @ p9 VTemsirolimus + everolimus ? 3 V _ L! M& U2 t: I
————————————————————7 V$ N1 _6 q$ F z0 p/ u
†Led to US FDA warning.
5 \0 K' x* @, N" d' R* b?: As yet unattempted combination.5 s) U; W/ q/ ]5 q, N/ N! d
|
显身卡
